
Category: Genomic
-
A Genome Every 200 Euros, a Decision Nobody Can Sign
The cost of reading a human genome has fallen so far that the accountant, not the geneticist, is now the bottleneck. Illumina’s NovaSeq X platform, deployed in fourteen European reference labs by early 2025, has pushed whole genome sequencing below 200 euros per sample, and Ultima Genomics is testing sub-100-dollar runs. What was once a…
-
The Autonomous Genomic Agent Europe Will Not Let Prescribe
magine a piece of software designed to do something clinically simple and legally impossible. It reads a patient’s whole-genome sequence, cross-references their electronic health records, identifies a pathogenic variant with a known targeted therapy, orders a confirmatory laboratory test, updates the treatment plan, and writes a prescription that lands in the pharmacy back-end. No human…
-
Europe’s Genomic Inflection Meets the Autonomous Agent
The genome has gone from museum exhibit to moving conveyor belt. Sequencers now decode three billion base pairs at a unit cost that would have looked absurd a decade ago, and the next layer of machinery, autonomous AI agents that interpret variants and trigger clinical actions, is already brushing against the walls of European hospitals.…
Popular Posts
- The Payment That Nobody Is Present to AuthorizeHow Autonomous AI Agents Meet PSD3, the Instant Payments Regulation,… Read more: The Payment That Nobody Is Present to Authorize
- Europe Will Certify the Robot. It Will Not Certify the LearningHow Autonomous AI Agents Collide with the Machinery Regulation, the… Read more: Europe Will Certify the Robot. It Will Not Certify the Learning
- A Genome Every 200 Euros, a Decision Nobody Can SignThe cost of reading a human genome has fallen so… Read more: A Genome Every 200 Euros, a Decision Nobody Can Sign
Archives
- September 2026 (1)
- August 2026 (2)
- July 2026 (3)
- June 2026 (1)
- May 2026 (3)
- March 2026 (1)
- January 2026 (1)
- July 2025 (2)
- April 2025 (2)
- March 2025 (4)
- February 2025 (10)
- January 2025 (3)






